



### I. Epidemiological profile

Population (UN Population Division)	2012	%
High transmission (>1 case per 1000 population)	6 540 000	44
Low transmission (0–1 cases per 1000 population)	1 340 000	9
Malaria-free (0 cases)	6 990 000	47
Total	14 870 000	



Parasites and vectors	
Major plasmodium species:	<i>P. falciparum</i> (56%), <i>P. vivax</i> (44%)
Major anopheles species:	<i>An. dirus</i> , <i>minimus</i> , <i>maculatus</i> , <i>sundaicus</i>
Programme phase: Control	

### II. Intervention policies and strategies



Intervention	Policies/strategies	Yes/No	Year adopted
<b>ITN</b>	ITNs/LLINs distributed free of charge	Yes	2000
	ITNs/LLINs distributed to all age groups	Yes	2000
<b>IRS</b>	IRS is recommended	No	–
	DDT is used for IRS	No	–
<b>Larval control</b>	Use of larval control	No	–
<b>IPT</b>	IPT used to prevent malaria during pregnancy	N/A	–
<b>Diagnosis</b>	Patients of all ages should receive diagnostic test	Yes	2000
	Malaria diagnosis is free of charge in the public sector	Yes	2000
<b>Treatment</b>	ACT is free for all ages in public sector	Yes	2000
	Artemisinin-based monotherapies withdrawn	Yes	2000
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for <i>P. falciparum</i>	No	–
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	–
	G6PD test is a requirement before treatment with primaquine	Yes	2012
	Directly observed treatment with primaquine is undertaken	No	–
	System for monitoring of adverse reaction to antimalarials exists	Yes	2010

Intervention	Policies/strategies	Yes/No	Year adopted				
<b>Surveillance</b>	ACD for case investigation (reactive)	No	–				
	ACD at community level of febrile cases (pro-active)	No	–				
	Mass screening is undertaken	No	–				
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	–				
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	–				
<b>Antimalaria treatment policy</b>			<b>Year adopted</b>				
First-line treatment of unconfirmed malaria		–	–				
First-line treatment of <i>P. falciparum</i>		AS+MQ; DHA-PPQ+PQ	–				
For treatment failure of <i>P. falciparum</i>		QN+T	–				
Treatment of severe malaria		AM; QN	–				
Treatment of <i>P. vivax</i>		DHA-PPQ	–				
Dosage of primaquine for radical treatment of <i>P. vivax</i>			–				
Type of RDT used		<i>Pf</i> + <i>Pv</i> specific (Combo)					
<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
DHA-PPQ	2008–2013	0	3.6	30.8	42 days	15	<i>P. f</i>
DHA-PPQ	2010–2011	0	0	0	28 days	3	<i>P. v</i>





### III. Financing



### IV. Coverage



### V. Impact



**Impact:** On track for >75% decrease in incidence 2000–2015